CA3139943A1 - Genome-based methods for reducing cardiovascular risk - Google Patents
Genome-based methods for reducing cardiovascular risk Download PDFInfo
- Publication number
- CA3139943A1 CA3139943A1 CA3139943A CA3139943A CA3139943A1 CA 3139943 A1 CA3139943 A1 CA 3139943A1 CA 3139943 A CA3139943 A CA 3139943A CA 3139943 A CA3139943 A CA 3139943A CA 3139943 A1 CA3139943 A1 CA 3139943A1
- Authority
- CA
- Canada
- Prior art keywords
- genetic variants
- patient
- prs
- cad
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/40—Population genetics; Linkage disequilibrium
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biochemistry (AREA)
- Data Mining & Analysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Artificial Intelligence (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962849670P | 2019-05-17 | 2019-05-17 | |
| US62/849,670 | 2019-05-17 | ||
| US201962933181P | 2019-11-08 | 2019-11-08 | |
| US62/933,181 | 2019-11-08 | ||
| PCT/US2020/033315 WO2020236670A1 (en) | 2019-05-17 | 2020-05-16 | Genome-based methods for reducing cardiovascular risk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3139943A1 true CA3139943A1 (en) | 2020-11-26 |
Family
ID=70978651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3139943A Pending CA3139943A1 (en) | 2019-05-17 | 2020-05-16 | Genome-based methods for reducing cardiovascular risk |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12264366B2 (enExample) |
| EP (2) | EP3969620B1 (enExample) |
| JP (2) | JP2022532423A (enExample) |
| CA (1) | CA3139943A1 (enExample) |
| MX (1) | MX2021014015A (enExample) |
| WO (1) | WO2020236670A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230057410A (ko) | 2020-08-25 | 2023-04-28 | 리제너론 파마슈티칼스 인코포레이티드 | Pcsk9 및 ldlr 조절인자를 사용한 패혈증 치료 |
| CN119998446A (zh) | 2022-06-07 | 2025-05-13 | 斯克里贝治疗公司 | 用于靶向pcsk9的组合物和方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2667894A1 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
| JP2010526555A (ja) * | 2007-05-11 | 2010-08-05 | タフツ・メディカル・センター | 加齢関連黄斑変性と関係するポリヌクレオチド及び患者のリスクを評価する方法 |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| PT3093663T (pt) | 2008-04-18 | 2018-10-19 | Critical Care Diagnostics Inc | Previsão do risco de eventos cardíacos adversos maiores |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CA2777698A1 (en) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Ax1 and ax189 pcsk9 antagonists and variants |
| AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| NZ602220A (en) | 2010-03-11 | 2014-10-31 | Rinat Neuroscience Corp | Antibodies with ph dependent antigen binding |
| CA2825778A1 (en) | 2011-01-28 | 2012-08-02 | Sanofi | Pharmaceutical compositions comprising human antibodies to pcsk9 |
| AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
| US20130244892A1 (en) * | 2012-02-12 | 2013-09-19 | Aram S. Adourian | Risk Factors and Prediction of Adverse Events |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| AR091462A1 (es) | 2012-06-15 | 2015-02-04 | Genentech Inc | Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso |
| NZ704771A (en) | 2012-08-13 | 2018-02-23 | Regeneron Pharma | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| IN2015DN01767A (enExample) | 2012-08-21 | 2015-05-29 | Critical Care Diagnostics Inc | |
| EP2968318A4 (en) | 2013-03-15 | 2016-12-14 | Shifa Biomedical Corp | ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US10329620B2 (en) * | 2017-01-12 | 2019-06-25 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| US20190017119A1 (en) * | 2017-07-12 | 2019-01-17 | The General Hospital Corporation | Genetic Risk Predictor |
-
2020
- 2020-05-16 EP EP20730885.9A patent/EP3969620B1/en active Active
- 2020-05-16 EP EP25181054.5A patent/EP4640848A3/en active Pending
- 2020-05-16 CA CA3139943A patent/CA3139943A1/en active Pending
- 2020-05-16 JP JP2021568564A patent/JP2022532423A/ja active Pending
- 2020-05-16 MX MX2021014015A patent/MX2021014015A/es unknown
- 2020-05-16 WO PCT/US2020/033315 patent/WO2020236670A1/en not_active Ceased
- 2020-05-16 US US16/876,030 patent/US12264366B2/en active Active
-
2025
- 2025-02-26 US US19/064,447 patent/US20250257406A1/en active Pending
- 2025-12-04 JP JP2025229455A patent/JP2026062658A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210002724A1 (en) | 2021-01-07 |
| EP3969620A1 (en) | 2022-03-23 |
| EP4640848A3 (en) | 2026-01-14 |
| US12264366B2 (en) | 2025-04-01 |
| MX2021014015A (es) | 2022-02-21 |
| EP3969620B1 (en) | 2025-06-25 |
| JP2026062658A (ja) | 2026-04-10 |
| EP4640848A2 (en) | 2025-10-29 |
| JP2022532423A (ja) | 2022-07-14 |
| US20250257406A1 (en) | 2025-08-14 |
| WO2020236670A1 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Walsh et al. | Genome-wide association studies of cardiovascular disease | |
| US20250257406A1 (en) | Genome-Based Methods For Reducing Cardiovascular Risk | |
| Van der Meer et al. | Boosting schizophrenia genetics by utilizing genetic overlap with brain morphology | |
| Moll et al. | Precision approaches to chronic obstructive pulmonary disease management | |
| Assimes et al. | Genetics: implications for prevention and management of coronary artery disease | |
| Taylor et al. | Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients | |
| JP2021072775A (ja) | 染色体相互作用の検出 | |
| Sivapalaratnam et al. | Monocyte gene expression signature of patients with early onset coronary artery disease | |
| Miller et al. | Precision medicine approaches to vascular disease: JACC Focus Seminar 2/5 | |
| Khan et al. | Advances and challenges for GWAS analysis in cardiac diseases: a focus on coronary artery disease (CAD) | |
| Hildebrandt et al. | The dual pro-inflammatory and bone-protective role of calcitonin gene-related peptide alpha in age-related osteoarthritis | |
| Yang et al. | Genome-wide mapping indicates that p73 and p63 co-occupy target sites and have similar dna-binding profiles in vivo | |
| Chang et al. | A genome-wide association study of chronic spontaneous urticaria risk and heterogeneity | |
| Schneider | Target therapy in SLE | |
| Sasidhar et al. | Genetics of coronary artery disease–A clinician's perspective | |
| Lu et al. | Identifying causes of fracture beyond bone mineral density: evidence from human genetics | |
| Satny et al. | Genetic risk score in patients with the APOE2/E2 genotype as a predictor of familial dysbetalipoproteinemia | |
| Faden et al. | Identification of a recognizable progressive skeletal dysplasia caused by RSPRY1 mutations | |
| HK40130500A (en) | Genome-based methods for reducing cardiovascular risk | |
| Mueller et al. | Small-RNA sequencing identifies serum microRNAs associated with abnormal electrocardiography findings in patients with Chagas disease | |
| JP7018544B2 (ja) | 心房細動の処置のためのブシンドロールを伴う方法および組成物 | |
| Siemelink et al. | Common variants associated with blood lipid levels do not affect carotid plaque composition | |
| Mishra et al. | Gene set analysis of transcriptomics data identifies new biological processes associated with early markers of atherosclerosis but not with those of osteoporosis: Atherosclerosis-osteoporosis co/multimorbidity study in the Young Finns Study | |
| Ichimura et al. | Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy | |
| SCALLOP consortium et al. | Mapping pQTLs of circulating inflammatory proteins identifies drivers of immune-related disease risk and novel therapeutic targets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220830 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241216 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250401 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250402 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250424 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250424 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250715 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250715 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260422 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260422 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260610 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260610 |